Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: Comparison between ischemic and nonischemic conditions

Doreen Richardt, Sebastian Wolfrum, Cathy Büttner, Ulrich Schäfer, Andreas Dendorfer, Thomas Kurz, Gert Richardt*

*Korrespondierende/r Autor/-in für diese Arbeit
1 Zitat (Scopus)

Abstract

ACE-inhibitors and AT1-receptor antagonists may exert part of their pharmacological actions by interference with angiotensin- and/or bradykinin-mediated prejunctional stimulation of cardiac norepinephrine release. As endogenous formation of angiotensin and bradykinin is increased in ischemia, we investigated the effects of the ACE-inhibitor ramiprilat and the AT1-receptor antagonist candesartan on cardiac norepinephrine release in isolated perfused rat hearts, under nonischemic and stop-flow conditions. Exocytotic release of endogenous norepinephrine was induced by electrical field stimulation and measured by HPLC. Paired stimulations were applied in each heart to obtain an intraindividual comparison of the effect of the pharmacological agent on norepinephrine release with the release under baseline conditions. The ACE-inhibitor ramiprilat (0.1-10 nM) and the AT1-receptor antagonist candesartan (1-100 nM) were studied during normal flow or in the fourth minute of stop-flow. Under nonischemic conditions, the ACE-inhibitor slightly reduced norepinephrine release at the highest concentration, while the AT1-receptor antagonist did not influence norepinephrine release in normoxia. Conversely, both substances significantly increased norepinephrine release during ischemia. Augmentation of norepinephrine release in ischemia by ramiprilat and candesartan was blocked by the bradykinin B2-receptor antagonist HOE 140 and, in case of candesartan, by the AT2-receptor antagonist PD 123319. The ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan enhance cardiac norepinephrine release selectively in ischemia by stimulating presynaptic bradykinin B2-receptors. Regarding the AT1-receptor antagonist, AT2-receptor activation is also involved in bradykinin-mediated prejunctional stimulation.

OriginalspracheEnglisch
ZeitschriftJournal of Cardiovascular Pharmacology
Jahrgang40
Ausgabenummer4
Seiten (von - bis)641-646
Seitenumfang6
ISSN0160-2446
DOIs
PublikationsstatusVeröffentlicht - 01.10.2002

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: Comparison between ischemic and nonischemic conditions“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren